BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Treprostinil (Yutrepia\, Liquidia) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Treprostinil (Yutrepia\, Liquidia)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07748000-521@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Treprostinil (Yutrepia\, Liquidia): Phase 2 readout est. (NCT077480
 00)
DESCRIPTION:Treprostinil (Yutrepia\, Liquidia)\, phase 2\, Systemic Scleros
 is.\nStudy: A Study of LIQ861 (Inhaled Treprostinil) in Adults With System
 ic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07748000
URL:https://assetmemo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759804-521@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Treprostinil (Yutrepia\, Liquidia): Phase 4 readout est. (NCT077598
 04)
DESCRIPTION:Treprostinil (Yutrepia\, Liquidia)\, phase 4\, Pulmonary Arteri
 al Hypertension.\nStudy: A Study of Inhaled Treprostinil (LIQ861) in Adult
 s With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07759804
URL:https://assetmemo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
